As of June 12, 2025, Erytech Pharma SA (ERYP.PA) reports a Gross Margin of 7775.20%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Comparing Erytech Pharma SA's Gross Margin to Peers
To better understand Erytech Pharma SA's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Erytech Pharma SA (ERYP.PA) | 7775.20% |
| OKYO Pharma Ltd (OKYO.L) | 7775.20% |
| BBS-Bioactive Bone Substitutes Oyj (BONEH.HE) | 7775.20% |
| Destiny Pharma PLC (DEST.L) | 7775.20% |
| Vicore Pharma Holding AB (VICO.ST) | 197.14% |
| Gensight Biologics SA (SIGHT.PA) | 188.37% |
Compared to its competitors, Erytech Pharma SA's Gross Margin is higher than all peers, indicating superior product pricing power or cost efficiency in production.